CD93 and nasopharyngeal carcinoma: The latest research revealed that CD93 was also highly expressed in tumor-associated vasculature, including nasopharyngeal carcinoma, glioblastoma, colorectal cancer, and pancreatic ductal adenocarcinoma (4–7).